FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nina Schooler

Research Profile

Disorders

Chemicals & Drugs

Activities & Behaviors

Schizophrenic Psychology

Concepts & Ideas

Procedures

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Peter J Weiden; Jeremy C Weedon; Abdel Elmouchtari; Nina R Schooler; Ayako Sunakawa-McMillan
Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
Nina R Schooler
Can we incorporate psychosocial treatment interventions into psychopharmacology clinical trials?
Nancy H Covell; Susan M Essock; Carlos T Jackson; Joseph P McEvoy; Ingrid A Rojas; Nina R Schooler; Thomas Stroup
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nina Schooler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Peter J Weiden; Jeremy C Weedon; Abdel Elmouchtari; Nina R Schooler; Ayako Sunakawa-McMillan
Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
The Journal of clinical psychiatry 2012;73(9):1224-33.
2012: Nina R Schooler
Can we incorporate psychosocial treatment interventions into psychopharmacology clinical trials?
The Journal of clinical psychiatry 2012;73(7):1023-4.
2012: Nancy H Covell; Susan M Essock; Carlos T Jackson; Joseph P McEvoy; Ingrid A Rojas; Nina R Schooler; Thomas Stroup
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
The Journal of clinical psychiatry 2012;73(5):669-75.
2011: Susan M Essock; Carlos Jackson; Joseph P McEvoy; Ingrid Rojas; Nina R Schooler; Thomas Stroup; Nancy H Covell
Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
The American journal of psychiatry 2011;168(7):702-8.
2011: Michael F Green; Nina R Schooler; Robert S Kern; Fred J Frese; Wendy Granberry; Philip D Harvey; Craig N Karson; Nancy Peters; Michelle Stewart; Larry J Seidman; John Sonnenberg; William S Stone; David Walling; Ellen Stover; Stephen R Marder
Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia.
The American journal of psychiatry 2011;168(4):400-7.
2011: Nina R Schooler
Jonathan O. Cole, MD (1925-2009): Innovator in clinical psychopharmacology and of the ECDEU/NCDEU tradition.
The Journal of clinical psychiatry 2011;72(3):286-7.
2010: Joseph Blader; Steven R Pliszka; Peter S Jensen; Nina R Schooler; Vivian Kafantaris
Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD.
Pediatrics 2010;126(4):e796-806.
2010: Carla M Canuso; Nina R Schooler; Jennifer Carothers; Ibrahim Turkoz; Colette Kosik-Gonzalez; Cynthia A Bossie; David Walling; Jean-Pierre Lindenmayer
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
Journal of clinical psychopharmacology 2010;30(5):487-95.
2010: Carla M Canuso; Jean-Pierre Lindenmayer; Colette Kosik-Gonzalez; Ibrahim Turkoz; Jennifer Carothers; Cynthia A Bossie; Nina R Schooler
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
The Journal of clinical psychiatry 2010;71(5):587-98.
2010: Aaron S Kemp; Nina R Schooler; Amir H Kalali; Larry Alphs; Ravi Anand; George Awad; Michael Davidson; Sanjay Dubé; Larry Ereshefsky; Georges Gharabawi; Andrew C Leon; Jean-Pierre Lepine; Steven G Potkin; An Vermeulen
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
Schizophrenia bulletin 2010;36(3):504-9.
2009: Joseph Blader; Nina R Schooler; Peter S Jensen; Steven R Pliszka; Vivian Kafantaris
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
The American journal of psychiatry 2009;166(12):1392-401.
2009: Peter Weiden; Nina R Schooler; Jeremy C Weedon; Abdel Elmouchtari; Ayako Sunakawa; Stephen M Goldfinger
A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
The Journal of clinical psychiatry 2009;70(10):1397-406.
2009: Robert A Lasser; Nina R Schooler; Mary Kujawa; John Docherty; Peter Weiden
A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy.
Psychiatry (Edgmont (Pa. : Township)) 2009;6(4):22-7.
2008: Stephen Irwin Deutsch; Richard B Rosse; Barbara L Schwartz; Nina R Schooler; Brooke L Gaskins; Katrice D Long; John Mastropaolo
Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2008;18(2):147-51.
2008: Stephen Irwin Deutsch; Barbara L Schwartz; Nina R Schooler; Richard B Rosse; John Mastropaolo; Brooke Gaskins
First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
Clinical neuropharmacology 2008;31(1):34-9.
2007: Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Joseph P McEvoy; Delbert Robinson; Nina R Schooler; Steven P Shon; Thomas Stroup; Del D Miller; Alexander Miller
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
The Journal of clinical psychiatry 2007;68(11):1751-62.
2007: Terry Goldberg; Robert S Goldman; Katherine Burdick; Anil Malhotra; Todd Lencz; Ramanbhai Patel; Margaret G Woerner; Nina R Schooler; John M Kane; Delbert Robinson
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Archives of general psychiatry 2007;64(10):1115-22.
2007: Robert W Buchanan; Daniel C Javitt; Stephen R Marder; Nina R Schooler; James M Gold; Robert P McMahon; Uriel Heresco-Levy; William T Carpenter
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
The American journal of psychiatry 2007;164(10):1593-602.
2007: Shaun M Eack; Nina R Schooler; Rohan Ganguli
Gerard E. Hogarty (1935--2006): combining science and humanism to improve the care of persons with schizophrenia.
Schizophrenia bulletin 2007;33(5):1056-62.
2006: Delbert Robinson; Margaret G Woerner; Barbara Napolitano; Ramanbhai Patel; Serge Sevy; Handan Gunduz-Bruce; Jose M Soto-Perello; Alan Mendelowitz; Ali Khadivi; Rachel Miller; Joanne McCormack; Beth S Lorell; Martin L Lesser; Nina R Schooler; John M Kane
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
The American journal of psychiatry 2006;163(12):2096-102.
2006: Ellen M Weissman; Carolyn W Zhu; Nina R Schooler; Raymond R Goetz; Susan M Essock
Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.
The Journal of clinical psychiatry 2006;67(9):1323-6.
2006: Nina R Schooler
Implications for future research of "medication-free research in early episode schizophrenia".
Schizophrenia bulletin 2006;32(2):297-8.
2006: Nina R Schooler
Relapse prevention and recovery in the treatment of schizophrenia.
The Journal of clinical psychiatry 2006;67 Suppl 5():19-23.
2005: Handan Gunduz-Bruce; Marjorie McMeniman; Delbert Robinson; Margaret G Woerner; John M Kane; Nina R Schooler; Jeffrey A Lieberman
Duration of untreated psychosis and time to treatment response for delusions and hallucinations.
The American journal of psychiatry 2005;162(10):1966-9.
2005: Serge Sevy; Murray H Rosenthal; Jose Alvir; Sabina Meyer; Hema Visweswaraiah; Handan Gunduz-Bruce; Nina R Schooler
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.
The Journal of clinical psychiatry 2005;66(7):839-43.
2005: Susan R McGurk; Cameron S Carter; Robert Goldman; Michael F Green; Stephen R Marder; Haiyi Xie; Nina R Schooler; John M Kane
The effects of clozapine and risperidone on spatial working memory in schizophrenia.
The American journal of psychiatry 2005;162(5):1013-6.
2005: David L Ginsberg; Nina R Schooler; Peter F Buckley; Philip D Harvey; Peter Weiden
Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning.
CNS spectrums 2005;10(2):1-13; discussion 14-15.
2005: Matcheri S Keshavan; Harpreet S Duggal; Gautami Veeragandham; Nancy M McLaughlin; Debra M Montrose; Gretchen L Haas; Nina R Schooler
Personality dimensions in first-episode psychoses.
The American journal of psychiatry 2005;162(1):102-9.
2004: Matcheri S Keshavan; Mujeeb U Shad; Paul H Soloff; Nina R Schooler
Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder.
Schizophrenia research 2004;71(1):97-101.
2004: Matcheri S Keshavan; Jonathan Rabinowitz; Goedele DeSmedt; Philip D Harvey; Nina R Schooler
Correlates of insight in first episode psychosis.
Schizophrenia research 2004;70(2-3):187-94.
2004: Stephen R Marder; Susan M Essock; Alexander Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy H Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven P Shon
Physical health monitoring of patients with schizophrenia.
The American journal of psychiatry 2004;161(8):1334-49.
2004: Serge Sevy; Hema Visweswaraiah; Claudia Mentschel; Stefan Leucht; Nina R Schooler
Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review.
The Journal of clinical psychiatry 2004;65(6):756-65.
2004: Alexander Miller; Catherine S Hall; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Larry Ereshefsky; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; A John Rush; Sy A Saeed; Nina R Schooler; Steven P Shon; Scott Stroup; Bernardo Tarin-Godoy
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
The Journal of clinical psychiatry 2004;65(4):500-8.
2004: Alan S Bellack; Nina R Schooler; Stephen R Marder; John M Kane; Clayton H Brown; Ye Yang
Do clozapine and risperidone affect social competence and problem solving?
The American journal of psychiatry 2004;161(2):364-7.
2003: Matcheri S Keshavan; Richard D Sanders; John A Sweeney; Vaibhav Atmanand Diwadkar; Gerald Goldstein; Jay W Pettegrew; Nina R Schooler
Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first-episode psychoses.
The American journal of psychiatry 2003;160(7):1298-304.
2003: Rory O'Connor; Nina R Schooler
Penultimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions.
Schizophrenia research 2003;60(2-3):319-20.
2003: Elizabeth Pappadopulos; James C Macintyre Ii; M Lynn Crismon; Robert L Findling; Richard P Malone; Albert Derivan; Nina R Schooler; Linmarie Sikich; Laurence Greenhill; Sarah B Schur; Chip J Felton; Harvey Kranzler; David M Rube; Jeffrey Sverd; Molly Finnerty; Scott Ketner; Sonja E Siennick; Peter S Jensen
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.
Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(2):145-61.
2003: Sarah B Schur; Linmarie Sikich; Robert L Findling; Richard P Malone; M Lynn Crismon; Albert Derivan; James C Macintyre Ii; Elizabeth Pappadopulos; Laurence Greenhill; Nina R Schooler; Kimberly Van Orden; Peter S Jensen
Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review.
Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(2):132-44.
2003: Matcheri S Keshavan; Gretchen Haas; Jean M Miewald; Debra M Montrose; Ravinder Reddy; Nina R Schooler; John A Sweeney
Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses.
Schizophrenia bulletin 2003;29(4):757-69.
2003: Nina R Schooler
Maintaining symptom control: review of ziprasidone long-term efficacy data.
The Journal of clinical psychiatry 2003;64 Suppl 19():26-32.
2003: Nina R Schooler
Relapse and rehospitalization: comparing oral and depot antipsychotics.
The Journal of clinical psychiatry 2003;64 Suppl 16():14-7.
2002: Daniel S Umbricht; William C Wirshing; Donna A Wirshing; Marjorie McMeniman; Nina R Schooler; Stephen R Marder; John M Kane
Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia.
The Journal of clinical psychiatry 2002;63(5):420-4.
2002: John M Kane; John M Davis; Nina R Schooler; Stephen Marder; Daniel E Casey; Benjamin Brauzer; Jim Mintz; Robert R Conley
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
The American journal of psychiatry 2002;159(4):554-60.
2002: Stephen R Marder; Susan M Essock; Alexander Miller; Robert W Buchanan; John M Davis; John M Kane; Jeffrey Lieberman; Nina R Schooler
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
Schizophrenia bulletin 2002;28(1):5-16.
2002: K N Roy Chengappa; J Vasile; Joseph Levine; Richard Ulrich; R Baker; A Gopalani; Nina R Schooler
Clozapine: its impact on aggressive behavior among patients in a state psychiatric hospital.
Schizophrenia research 2002;53(1-2):1-6.
2001: John M Kane; S R Marder; Nina R Schooler; William C Wirshing; D Umbricht; Robert W Baker; Donna A Wirshing; A Safferman; Rohan Ganguli; Marjorie McMeniman; Michael Borenstein
Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
Archives of general psychiatry 2001;58(10):965-72.
2001: Kim T Mueser; Anjana Sengupta; Nina R Schooler; Alan S Bellack; Haiyi Xie; Ira D Glick; S J Keith
Family treatment and medication dosage reduction in schizophrenia: effects on patient social functioning, family attitudes, and burden.
Journal of consulting and clinical psychology 2001;69(1):3-12.
2001: Nina R Schooler
The statistical comparison of clinical trials.
The Journal of clinical psychiatry 2001;62 Suppl 9():35-7; discussion 38-9.
2000: Alan S Bellack; Gretchen L Haas; Nina R Schooler; J D Flory
Effects of behavioural family management on family communication and patient outcomes in schizophrenia.
The British journal of psychiatry : the journal of mental science 2000;177():434-9.
1999: Deanna M Barch; Cameron S Carter; WM Perlstein; J Baird; Jonathan D Cohen; Nina R Schooler
Increased stroop facilitation effects in schizophrenia are not due to increased automatic spreading activation.
Schizophrenia research 1999;39(1):51-64.
1999: K N Roy Chengappa; S Sheth; Jaspreet S Brar; Haranath Parepally; S Marcus; A Gopalani; A Palmer; Robert W Baker; Nina R Schooler
Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.
The Journal of clinical psychiatry 1999;60(6):373-8.
1999: Matcheri S Keshavan; Cameron S Carter; G Haas; Nina R Schooler
Schizophreniform disorder: exception proves the rule.
The American journal of psychiatry 1999;156(6):971-2.
1999: John DeQuardo; Matcheri S Keshavan; Fred L Bookstein; W W Bagwell; W D Green; John A Sweeney; Gretchen L Haas; Rajiv Tandon; Nina R Schooler; Jay W Pettegrew
Landmark-based morphometric analysis of first-episode schizophrenia.
Biological psychiatry 1999;45(10):1321-8.
1998: John A Sweeney; Beatriz Luna; N M Srinivasagam; Matcheri S Keshavan; Nina R Schooler; Gretchen L Haas; J R Carl
Eye tracking abnormalities in schizophrenia: evidence for dysfunction in the frontal eye fields.
Biological psychiatry 1998;44(8):698-708.
1998: S Ahmed; K N Roy Chengappa; V R Naidu; Robert W Baker; Haranath Parepally; Nina R Schooler
Clozapine withdrawal-emergent dystonias and dyskinesias: a case series.
The Journal of clinical psychiatry 1998;59(9):472-7.
1998: Matcheri S Keshavan; Gretchen L Haas; C E Kahn; E Aguilar; Elizabeth Dick; Nina R Schooler; John A Sweeney; Jay W Pettegrew
Superior temporal gyrus and the course of early schizophrenia: progressive, static, or reversible?
Journal of psychiatric research 1998;32(3-4):161-7.
1998: J Thompson; K N Roy Chengappa; Chester B Good; Robert W Baker; R P Kiewe; J Bezner; Nina R Schooler
Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment.
International clinical psychopharmacology 1998;13(2):95-8.
1998: Matcheri S Keshavan; Nina R Schooler; John A Sweeney; Gretchen L Haas; Jay W Pettegrew
Research and treatment strategies in first-episode psychoses. The Pittsburgh experience.
The British journal of psychiatry. Supplement 1998;172(33):60-5.
1997: Nina R Schooler
New antipsychotic medications: strategies for evaluation and selected findings.
Schizophrenia research 1997;27(2-3):249-59.
1997: Nina R Schooler; S J Keith; J B Severe; S M Matthews; Alan S Bellack; Ira D Glick; W A Hargreaves; John M Kane; P T Ninan; A Frances; M Jacobs; Jeffrey A Lieberman; R Mance; George M Simpson; Margaret G Woerner
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.
Archives of general psychiatry 1997;54(5):453-63.
1997: William T Carpenter; Nina R Schooler; John M Kane
The rationale and ethics of medication-free research in schizophrenia.
Archives of general psychiatry 1997;54(5):401-7.
1997: John A Sweeney; Kenneth S. Bauer; Matcheri S Keshavan; Gretchen L Haas; Nina R Schooler; Patricia D Kroboth
Adverse effects of risperidone on eye movement activity: a comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1997;16(3):217-28.
1996: D Ames; William C Wirshing; Robert W Baker; D S Umbricht; A B Sun; J Carter; Nina R Schooler; John M Kane; Stephen R Marder
Predictive value of eosinophilia for neutropenia during clozapine treatment.
The Journal of clinical psychiatry 1996;57(12):579-81.
1996: Nina R Schooler; J B Severe; Ira D Glick; W A Hargreaves; Samuel J Keith; Peter Weiden
Transition from acute to maintenance treatment: prediction of stabilization.
International clinical psychopharmacology 1996;11 Suppl 2():85-91.
1996: Robert W Baker; D Ames; D S Umbricht; K N Roy Chengappa; Nina R Schooler
Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
Psychopharmacology bulletin 1996;32(1):89-93.
1996: K N Roy Chengappa; A Gopalani; M K Haught; K McChesney; Robert W Baker; Nina R Schooler
The treatment of clozapine-associated agranulocytosis with granulocyte colony-stimulating factor (G-CSF).
Psychopharmacology bulletin 1996;32(1):111-21.
1995: Nina R Schooler
Integration of family and drug treatment strategies in the treatment of schizophrenia: a selective review.
International clinical psychopharmacology 1995;10 Suppl 3():73-80.
1995: Nina R Schooler; Samuel J Keith; J B Severe; S M Matthews
Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies.
The Psychiatric quarterly 1995;66(4):279-92.
1994: S Steingard; M Allen; Nina R Schooler
A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
The Journal of clinical psychiatry 1994;55(11):470-2.
1994: Kim T Mueser; Steven Sayers; Nina R Schooler; R M Mance; Gretchen L Haas
A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms.
The American journal of psychiatry 1994;151(10):1453-62.
1994: Richard D Sanders; Matcheri S Keshavan; Nina R Schooler
Neurological examination abnormalities in neuroleptic-naive patients with first-break schizophrenia: preliminary results.
The American journal of psychiatry 1994;151(8):1231-3.
1994: Nina R Schooler
Negative symptoms in schizophrenia: assessment of the effect of risperidone.
The Journal of clinical psychiatry 1994;55 Suppl():22-8.
1994: K N Roy Chengappa; M D Shelton; Robert W Baker; Nina R Schooler; J Baird; J Delaney
The prevalence of akathisia in patients receiving stable doses of clozapine.
The Journal of clinical psychiatry 1994;55(4):142-5.
1993: Nina R Schooler
Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis.
The British journal of psychiatry. Supplement 1993;(22):58-65.
1993: Joseph P McEvoy; Nina R Schooler; E Friedman; S Steingard; M Allen
Use of psychopathology vignettes by patients with schizophrenia or schizoaffective disorder and by mental health professionals to judge patients' insight.
The American journal of psychiatry 1993;150(11):1649-53.
1993: S Steingard; K N Roy Chengappa; Robert W Baker; Nina R Schooler
Clozapine, obsessive symptoms, and serotonergic mechanisms.
The American journal of psychiatry 1993;150(9):1435.
1993: D E Myers; Nina R Schooler; Thomas G Zullo; H Levin
A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia.
The Journal of prosthetic dentistry 1993;69(6):578-81.
1993: John M Davis; John M Kane; S R Marder; B Brauzer; B Gierl; Nina R Schooler; Daniel E Casey; M Hassan
Dose response of prophylactic antipsychotics.
The Journal of clinical psychiatry 1993;54 Suppl():24-30.
1993: Peter Weiden; Nina R Schooler; J B Severe; J H Lee; S C Schulz
Stabilization and depot neuroleptic dosages.
Psychopharmacology bulletin 1993;29(2):269-75.
1993: Nina R Schooler; Samuel J Keith
The clinical research base for the treatment of schizophrenia.
Psychopharmacology bulletin 1993;29(4):431-46.
1992: Robert W Baker; K N Roy Chengappa; J W Baird; S Steingard; M A Christ; Nina R Schooler
Emergence of obsessive compulsive symptoms during treatment with clozapine.
The Journal of clinical psychiatry 1992;53(12):439-42.
1992: Matcheri S Keshavan; Nina R Schooler
First-episode studies in schizophrenia: criteria and characterization.
Schizophrenia bulletin 1992;18(3):491-513.
1991: Margaret G Woerner; John M Kane; Jeffrey A Lieberman; Jose Alvir; K J Bergmann; Michael Borenstein; Nina R Schooler; S Mukherjee; J Rotrosen; M Rubinstein
The prevalence of tardive dyskinesia.
Journal of clinical psychopharmacology 1991;11(1):34-42.
1991: Nina R Schooler
Maintenance medication for schizophrenia: strategies for dose reduction.
Schizophrenia bulletin 1991;17(2):311-24.
1989: J B Severe; Nina R Schooler; J H Lee; G Haas; K T Mueser; P Rosen; D Shortell; M Shumway
Ensuring data quality in a multicenter clinical trial: remote site data entry, central coordination and feedback.
Psychopharmacology bulletin 1989;25(3):488-90.
1989: Nina R Schooler; Samuel J Keith; J B Severe; S Matthews
Acute treatment response and short term outcome in schizophrenia: first results of the NIMH treatment strategies in schizophrenia study. Treatment Strategies in Schizophrenia Collaborative Study Group.
Psychopharmacology bulletin 1989;25(3):331-5.
1988: Jose Alvir; Nina R Schooler; Michael Borenstein; Margaret G Woerner; John M Kane
The reliability of a shortened version of the SCL-90.
Psychopharmacology bulletin 1988;24(2):242-6.
1982: M R Mandel; J B Severe; Nina R Schooler; A J Gelenberg; M Mieske
Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics.
Archives of general psychiatry 1982;39(2):197-203.
1980: Nina R Schooler; J Levine; J B Severe; B Brauzer; A DiMascio; G L Klerman; V B Tuason
Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate.
Archives of general psychiatry 1980;37(1):16-24.